Drug Eluting Stents Articles

Washington, DC: When the US Food and Drug Administration (FDA) approved 'Endeavor,' the drug-coated Medtronic stent earlier this year, it did so amidst a storm of controversy as to whether or not the stents promote potentially dire blood clots in heart attack patients. Drug eluting stents are still under FDA scrutiny, but as 2008 dawned there was little conclusive evidence to prove the suspicion as fact.

Washington, DC: The stenting for profit industry hit a major snag on March 1, 2007, when the US House Oversight and Government Reform Committee, ordered Johnson & Johnson and Boston Scientific to turn over documents related to their sales and marketing activities for drug-eluting stents.

Washington, DC: In addition to the federal investigations into the off-label marketing of drug eluting stents by Boston Scientific and Johnson & Johnson, on May 10, 2007, Rep Maurice Hinchey (D-NY), who serves on the House Appropriations Subcommittee, announced the introduction of the FDA reform bill which addresses the issue of doctors using products for unapproved uses, which usually occurs without the patient's knowledge or consent.

Washington DC: The stenting for profit industry may soon be history. On March 1, 2007, the chairman of the US House Oversight and Government Reform Committee, Henry Waxman (D-CA), ordered Johnson & Johnson and Boston Scientific to turn over documents as part of an investigation into the off-label marketing of drug-eluting stents.